Glutaminergic Agents for Cocaine Abuse - 5

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000280

Purpose

The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Nimodipine	Phase I

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Glutaminergic Agents for Cocaine Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000280

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

Study ID Numbers:	NIDA-09250-5, P50-09250-5
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000280
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Calcium, Dietary
Mental Disorders
Substance-Related Disorders

Nimodipine
Disorders of Environmental Origin
Cocaine

Additional relevant MeSH terms:

Membrane Transport Modulators
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Calcium Channel Blockers
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009